Low Dose Rifaximin DER for Sickle Cell Disease

"This medical study seeks 60 qualified volunteers who are between eighteen and seventy years old, have anemia due to sickle cell disease (SCD) of any genotype, possess a documented Absolute Neutrophil Count of at least 1.0 x 109/L, Platelets of 75 x 109/L or more, Glomerular filtration rate 45 mL/min/1.73 m2 as determined by the CKD-EPI formula, Total bilirubin count no higher than 15 mg/dL, and experienced two Vaso-Occlusive Crises within 12 months prior to Screening. Furthermore,"

"Rifaximin DER, administered in low doses, is frequently used to prevent clostridium difficile infection recurrence. It may also help treat bacterial infections and gastrointestinal conditions such as irritable bowel syndrome (IBS) or diarrhea."

"Affirmative. According to clinicaltrials.gov, this medical experiment is presently enrolling volunteers and has been doing so since March 22nd 2022. The most recent update was on August 29th of the same year, with a total of 60 participants sought from 3 trial hubs."

"In 2009, Low Dose Rifaximin DER was first studied at the New mexico VA Healthcare System. Since then, 18369 research trials have been completed and 23 are currently running with a concentration in Atlanta, Georgia."

"Given the Phase 2 nature of this trial, there is a sufficient amount of evidence to suggest that Low Dose Rifaximin DER has an acceptable level of safety; thus it received a score of 2."

"According to the prerequisites for enrollment, adults aged 18-70 are welcome to take part in this trial."

"Affirmative. Per the data present on clinicaltrials.gov, enrollment for this medical trial is currently open as of August 29th 2022. Initially posted in March 22nd 2022, 60 individuals are sought from 3 different locations to join the study."